Diana Melissaratos

Diana Melissaratos

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Biology
Verified
Journal Article
Open access
PDF file
TOTeresa Osorio
Teresa Osorio
ESErnest R. Scoma
Ernest R. Scoma
DSDaniel Shain
Daniel Shain
DMDiana Melissaratos
Diana Melissaratos
LRLindsey M. Riggs
Lindsey M. Riggs
MTMaria E. Solesio Torregrosa
Maria E. Solesio Torregrosa
The inorganic polymer, polyphosphate (polyP), is present in all organisms examined to date with putative functions ranging from the maintenance of bioenergetics to stress resilience and protein homeostasis. Bioenergetics in the glacier-obligate, segmented worm, Mesenchytraeus solifugus, is characterized by a paradoxical increase in intracellular ATP levels as temperatures decline. We show here that steady-state, mitochondrial polyP levels vary among species of Annelida, but were elevated only in M. solifugus in response to thermal stress. In contrast, polyP levels decreased with temperature in the mesophilic worm, Enchytraeus crypticus. These results identify fundamentally different bioenergetic strategies between closely related annelid worms, and suggest that I worm mitochondria maintain ATP and polyP in a dynamic equilibrium.

26 November 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
NWNicole Wilski
Nicole Wilski
DEDan A. Erkes
Dan A. Erkes
TPTimothy J. Purwin
Timothy J. Purwin
DMDiana Melissaratos
Diana Melissaratos
CSCasey D. Stefanski
Casey D. Stefanski
AAAndrew E. Aplin
Andrew E. Aplin
Treatment of melanoma with BRAF inhibitors plus MEK inhibitors (BRAFi + MEKi) stimulates an intratumoral immune response, in part through pyroptosis mediated by the pore-forming protein gasdermin E (GSDME/Gsdme). How GSDME mediates effects on tumoral immunity is not well characterized. Using single-cell RNA sequencing and flow cytometry in BRAFi + MEKi–treated melanoma, we show herein that isogenic Gsdme knockout (KO) tumors show decreased infiltration with T cells, natural killer (NK) cells, and regulatory T cells (Treg) compared with control tumors. Infiltrated Tregs in Gsdme KO tumors displayed decreased expression of the IL2 receptor and phenotypic markers associated with suppressive function. Furthermore, intratumoral frequency of phenotypically suppressive Tregs was decreased after BRAFi + MEKi treatment in Gsdme KO tumors engineered to express a pyroptosis-defective mutant form of Gsdme (T6E) compared with Gsdme KO tumors engineered to reexpress wild-type Gsdme. Combining BRAFi + MEKi with a TLR9 agonist limited the regrowth of Gsdme-deficient tumors, and this was associated with a further reduction in intratumoral Tregs. Overall, we show a critical role of GSDME in the modulation of intratumoral immune cells in BRAFi + MEKi–treated melanoma.

4 March 2026
Verified
Other
Open access
NWNicole Wilski
Nicole Wilski
DEDan A. Erkes
Dan A. Erkes
TPTimothy J. Purwin
Timothy J. Purwin
DMDiana Melissaratos
Diana Melissaratos
CSCasey D. Stefanski
Casey D. Stefanski
AAAndrew E. Aplin
Andrew E. Aplin
Figure S1 from Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy–Treated Melanoma

4 March 2026
Verified
Other
Open access
NWNicole Wilski
Nicole Wilski
DEDan A. Erkes
Dan A. Erkes
TPTimothy J. Purwin
Timothy J. Purwin
DMDiana Melissaratos
Diana Melissaratos
CSCasey D. Stefanski
Casey D. Stefanski
AAAndrew E. Aplin
Andrew E. Aplin
Treatment of melanoma with BRAF inhibitors plus MEK inhibitors (BRAFi + MEKi) stimulates an intratumoral immune response, in part through pyroptosis mediated by the pore-forming protein gasdermin E (GSDME/Gsdme). How GSDME mediates effects on tumoral immunity is not well characterized. Using single-cell RNA sequencing and flow cytometry in BRAFi + MEKi–treated melanoma, we show herein that isogenic Gsdme knockout (KO) tumors show decreased infiltration with T cells, natural killer (NK) cells, and regulatory T cells (Treg) compared with control tumors. Infiltrated Tregs in Gsdme KO tumors displayed decreased expression of the IL2 receptor and phenotypic markers associated with suppressive function. Furthermore, intratumoral frequency of phenotypically suppressive Tregs was decreased after BRAFi + MEKi treatment in Gsdme KO tumors engineered to express a pyroptosis-defective mutant form of Gsdme (T6E) compared with Gsdme KO tumors engineered to reexpress wild-type Gsdme. Combining BRAFi + MEKi with a TLR9 agonist limited the regrowth of Gsdme-deficient tumors, and this was associated with a further reduction in intratumoral Tregs. Overall, we show a critical role of GSDME in the modulation of intratumoral immune cells in BRAFi + MEKi–treated melanoma.


4 March 2026
Verified
Other
Open access
NWNicole Wilski
Nicole Wilski
DEDan A. Erkes
Dan A. Erkes
TPTimothy J. Purwin
Timothy J. Purwin
DMDiana Melissaratos
Diana Melissaratos
CSCasey D. Stefanski
Casey D. Stefanski
AAAndrew E. Aplin
Andrew E. Aplin
Figure S5 from Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy–Treated Melanoma